Lauren Reiman - Dissemin

All papers authored by Lauren Reiman

This paper was not found in any repository, but could be made available legally by the author.

2024 Lorraine N. Davis

, Zachary J. Walker

, Lauren T. Reiman

, Sarah E. Parzych

, Brett M. Stevens

, Craig T. Jordan

, Peter A. Forsberg

, Daniel W. Sherbenou

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Zachary J. Walker, Katherine F. Vaeth, Amber Baldwin, Denis J. Ohlstrom, Lauren T. Reiman

, Beau M. Idler, Brett M. Stevens, Neelanjan Mukherjee, Daniel W. Sherbenou

Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple Myeloma

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Table 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 3 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 4 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 2 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Supplementary Figure 5 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Alana L. Keller, Lauren T. Reiman

, Olivia Perez de Acha

, Sarah E. Parzych

, Peter A. Forsberg, Peter S. Kim, Kamlesh Bisht

, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Data from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Upload

Xiaocheng Chen, Oi Kwan Wong, Lauren Reiman